Wisconsin HAI Long-Term Care Education Series August 22, 2024



SYPHILIS 101



/ //

Syphilis Surveillance Coordinator: Craig Berger (He/Him) 608-266-1323 craig.berger@dhs.Wisconsin.gov

Wisconsin Department of Health Services


SYPHILIS IS HARD!!!!!

- Providers have 100's of diseases they need to know.
- DIS concentrate on 4 main diseases, per CDC recommendations; these include
 - ► Syphilis
 - ► Gonorrhea
 - ► Chlamydia
 - ► HIV
- Please reach out to your reginal DIS for assistance (or me).

STI data should be interpreted with caution. It may be underreported, unevenly reported, and incomplete.




Cases of STIs should be reported to LTHDs first.



Gender Reporting


- Reporting may not be inclusive to gender.
- Providers may/may not report correctly.
- Using gender(s) marked by patients knowing some may not be comfortable reporting unassigned gender.



Chlamydia is the Most Commonly Reported STI

Of the 33,791 STI cases reported in 2023, Chlamydia accounted for 74% by followed by gonorrhea at 21% and syphilis at 5%.


Number of Sexually Transmitted Infections Reported in Wisconsin, 2023



Note: Includes all (Wisconsin, out of jurisdiction cases and correctional cases) reported cases.

More Wisconsin Counties Reporting Increased Syphilis Rates in 2023 than in 2013


Syphilis rates of reported cases 2013 and 2023



Syphilis Cases Have Increased Since 2019

Syphilis cases increased by 206.7% from 2019 to 2023.


Trend of reported cases of syphilis (all stages including congenital) 2019–2023




There Were Fewer Syphilis Cases Reported in 2023 than in 2022

The reported number of syphilis cases decreased by 6.4% in 2023 compared to 2022.


Trend of reported cases of syphilis (all stages including congenital) 2019–2023



Wisconsin ranked highest among its neighboring states for primary and secondary syphilis rates per 100,000 people in 2022.




Black and Hispanic People are Disproportionately Impacted by Syphilis



Reported Number of Congenital Syphilis Cases Increased Until 2022

Reported cases of congenital syphilis in Wisconsin, 2019–2023



Wisconsin Regional Data


2023 Unpublished Data *do not release*



Region		2019	2020	2021	2022	2023
Southern	Primary Secondary Early Late	8 11 25 42	30 22 32 62	34 36 46 71	31 40 38 106	31 33 58 125
Northern	Primary Secondary Early Late	2 1 1 9	4 3 1 4	9 10 6 18	11 11 8 20	3 9 8 37
Western	Primary Secondary Early Late	5 10 7 22	5 1 7 17	15 12 6 28	18 16 21 41	8 18 24 36
Northeast	Primary Secondary Early Late	9 10 15 49	18 13 18 32	35 17 25 72	29 30 37 84	35 25 32 102
Southeast	F Primary Secondary Early Late	50 80 149 81	153 116 169 115	274 282 292 296	249 308 300 471	165 207 237 513
Congenit	al(Statewide)	2	1	8	28	25

Congenital syphilis cases **increased by 580%** during the pandemic from 2020 to 2022.


Congenital syphilis cases, 2013 - 2022



DHS News Release

- DHS recommends testing pregnant people for syphilis in any health care setting.
- DHS recommends across the board syphilis testing at first prenatal visit, 28 weeks, and at delivery.

https://www.dhs.wisconsin.gov/news/releases/101023.htm



WISCONSIN DEPARTMENT

FOR IMMEDIATE RELEASE

October 10, 2023

Contact Elizabeth Goodsitt, 608-266-1683 Jennifer Miller, 608-266-1683

Syphilis Cases Continue to Rise in Wisconsin-Affecting Babies, Teens, and Adults

DHS is calling on medical providers to increase syphilis screening and testing during pregnancy

PCN Shortage

A recent shortage of benzathine penicillin G could cause possible disruption in syphilis treatment.

- Treat patients with early syphilis who are not pregnant and are likely to tolerate oral therapy with oral doxycycline.
- Prioritize penicillin for pregnant people.

Wisconsin DHS Health Alert #56: Current Drug Shortages Affecting Treatment of Syphilis and Gonorrhea

Wisconsin Department of Health Services sent this bulletin at 07/19/2023 12:11 PM CDT



DHS Health Alert Network

Current Drug Shortages Affecting Treatment of Syphilis and Gonorrhea

Bureau of Communicable Diseases

July 19, 2023

Key points

- A recent shortage of penicillin G benzathine could cause a disruption in treatment for those who have active syphilis or are contacts to known syphilis cases. Treatment with oral doxycycline for patients with early syphilis who are not pregnant and are likely to tolerate oral therapy, while prioritizing penicillin for pregnant people, may be necessary.
- Gentamicin is an alternative gonococcal treatment recommended for patients with known or self-reported allergy to cephalosporins. If gentamicin is not available due to reported shortages, the CDC (Centers for Disease Control and Prevention) recommends treatment with a single dose of 2 grams of azithromycin.

Background

The Food and Drug Administration (FDA) has issued a notice of <u>limited availability of STI</u> testing and treatment products.

A recent shortage of penicillin G benzathine injectable suspension products (Bicillin L-A®)

Two Types of Tests



Treponemal Test

EIA/IGG/FTA/MHTP/TPPA

- Detects syphilis antibodies
- Remains detectable for life even after treatment
- Will appear reactive before RPR/VDRL
- Can take up to ten weeks after exposure to show reactive

Non-Treponemal

RPR/VDRL

- Response to cardio lipid antigens
- May appear non-reactive either early or late in an infection
- Non-treponemal tests should have a titer
 - 1:1, 1:2, 1:4 etc

Common Syphilis Serologic Tests

Test	Full Name	Туре	Target	Notes
RPR	Rapid Plasma Reagin	Non- treponemal	Cardiolipin Antibodies	Quantitative results reported as a titer.
VDRL	Veneral Disease Research Laboratory	Non- treponemal	Cardiolipin Antibodies	Quantitative results reported as a titer. Only test approved for CSF (cerebrospinal fluid) specimens.
FTA- ABS	Fluorescent Treponemal Antibody- Absorption	Treponemal	<i>T. pallidum</i> Antibodies	
TP-PA	<i>Treponema pallidum-</i> particle agglutination	Treponemal	<i>T. pallidum</i> Antibodies	
МНА-ТР	Microhemagglutination- <i>Treponema pallidum</i>	Treponemal	<i>T. pallidum</i> Antibodies	
EIA	Enzyme immunoassay	Treponemal	<i>T. pallidum</i> Antibodies	May be initial test in reverse sequencing algorithm.
CIA	Chemiluminescent immunoassay	Treponemal	<i>T. pallidum</i> Antibodies	May be initial test in reverse sequencing algorithm.

Note: This table is not exhaustive of all the tests available for diagnosing syphilis.


Two CDC-Recognized Algorithms

- Treponemal and non-treponemal tests must be used together to establish a syphilis diagnosis.
- CDC recognizes two serologic algorithms
 - Traditional
 - Reverse

Traditional Algorithm

- Begins with an RPR/VDRL (Non-treponemal)
- If non-reactive testing stops. *not a case*.
- If reactive, reflex to a Treponemal test.
- If both reactive it is a case of syphilis
 determine stage of infection or if previously treated infection.
- If Non-reactive *not a case*.
- Determining stage of infection is a whole other conversation.


Traditional Syphilis Testing Algorithm



Reverse Algorithm

- Begin with a less specific Treponemal test
- If non-reactive testing stops *not a case*.
- If reactive, reflex to a Non-treponemal test.
- If reactive testing stops *determine stage of disease or if previously treated infection*.
- If results are discordant, should reflex to another more specific Treponemal test.
- Gold standard is the TP-PA, other test can be used.
- If non-reactive *not a case*.
- If reactive *determine stage of disease or if previously treated infection*.

Reverse Syphilis Testing Algorithm



PRIMARY SYPHILIS



- Chancre must be present and seen by provider
 - Chancre is normally painless

Treatment:

-2.4 MU Benzathine Penicillin G IM 1X -14 days Doxycycleine 100 Mg BID

SECONDARY SYPHILIS



• Plantar Palmer Rash

- Palms of hands/souls of feet
- Also presents full body (torso), forearms, legs
 - This presentation must be bilateral
- Condyloma Lata
 - Cluster of painful blisters

Treatment: -1 dose PCN -14 days Doxy

EARLY LATENT / EARLY NON-PRIMARY NON-SECONDARY SYPHILIS

- Symptom Free
- Must prove known exposure to Primary or Secondary Stage
- A known negative lab within the last year.
- Treatment
- 1 dose PCN
- 14 days Doxy

LATE LATENT / LATE OR UNKNOWN DURATION

- No known exposure
- Previous testing over 12 months or no known previous testing
- If unable to determine as an Early Stage of Syphilis we always defer to this.
- Treatment
 - 3 doses PCN G 2.4 MU given 7 days apart for 3 weeks
 - 28 Days Doxy 100mg BID

Neurosyphilis

• All stages of disease **must** have at least a minimal neurologic examination.

• Neurosyphilis can occur at any stage.



After treatment recommendations

- Repeat testing at 6 and 12 months
 - At a minimum annually thereafter.
- Can take up to 12 months to get a four-fold decrease.
- May not have a full four-fold decrease if the titer starts low or obviously if it is nonreactive.
- There may be an initial titer spike shortly after treatment, this is why we want to wait a minimum of three months after treatment.



Reporting

- Per State Statutes ALL reactive syphilis cases are required to be reported.
- Report can either be via WEDSS, paper fax, or call (please don't do that).
- Even after report we may call for clarification.
- Following slides if completed via web report we probably will not need a follow up call.
- <u>https://www.dhs.wisconsin.gov/library/collectio</u> <u>n/f-44243</u> (plain ol' syphilis)
- <u>https://www.dhs.wisconsin.gov/forms/f4/f4424</u>
 <u>3a.pdf</u> (congenital syphilis)

Patient tab

A tab to document any patient locating information.

Document the information in all text fields highlighted in yellow **plus** the fields below:

- Home, cell, or work phone number
- Email (if applicable)
- Primary language
- Pregnancy and delivery date (if applicable)
- Marital status
- STI additional demographics (if applicable)

Disease Incie	dent	8 😫	3 🧥 🖄	💖 🍪 🔒 🤜	1 🖩 🛸 🌖 🖇) 📰 i
Patient: Test, Test DOB: 10/01/1950		Patient ID: 2102897 Disease: SYPHILIS	Cardina (United States)	Incident ID: Pro/Res Sta	37371125 tus: Final/Unknown	
Patient	Syph-LabClinical	Syph-Risk !	Syph-Intervention	Investigation		
* Disease Being Re	eported SYPHILIS REAC	TOR	~]		
Name					Primary Language	
* Last Name	* First Name	Middle Name	Name Suffix		Spanish	~
Test	Test	Z			* Ethnicity	
Future Client No.	* DOB (MN	I/DD/YYYY)	Age Months D	ays	Hispanic or Latino	~
	10/01/1950	0	72		* Race	
Address Number 8	k Street		Apartment/Unit N	umber	American Indian	or Alaska
1234 ADDRESS					Native	
* City	* State		* Zip		Asian	
Hortonville	WI	10	54942		Asidii	

If more than one test is performed, add additional tests by using the add button.

Laboratory Testing			
ID-001			
Collection date			
Provider (Doctor, Clinic)	Attending Physician	Doctor's Name	
Specimen source	If other, please speci	fy	
✓			
Type of test	If other serologic tes	t, please specify	
✓			
	Qualitative result		
Nontreponemal serologic syphilis test result	Indeterminate	Negative	Non-Reactive
	O Positive	Reactive	O Unknown
	O Weakly-reactive	O Quantity not sufficient	O Contaminated specimen
Quantitative test result, if applicable (titer)	Date result sent from	ı lab	
			Delete
			Add

STI & DGI Signs and Symptoms

A section to document any signs or symptoms the patient may have experienced in the past or present. This section will also help the interviewer in determining the stage of syphilis the patient is in. Remember, any syphilis symptoms **must** be seen by a provider to determine stage of syphilis.

Document any signs or symptoms specific to syphilis in the fields below:

- STI signs or symptoms or if other, please specify. Common syphilis symptoms: chancre, sores, lesions, ulcers, rash, alopecia (hair loss), condylomata lata, pharyngitis (sore throat), and mucous patch
- Anatomic site or if other, please specify
- Earliest observation
- Duration (days)
- When did the patient first seek medical care for symptom

If more than one symptom, add additional symptoms by using the add button. If there are no symptoms, leave the section blank.

STI & DGI Signs and Symptoms

ID-001

When documenting symptoms please use Other for chills, malaise and pain unless already on the list under STI signs/symptoms. When documenting Anatomic site please use other for joints.

STI signs/sym	ptoms		~	If other, please specify		
Anatomic site			_	If other, please specify		
Earliest observ	vation date		~	Duration (days)		
When did the p	patient first seek medie	cal care for symptom				
In what type of symptom	f facility did the patien	t seek medical care for		If other facility, specify		
symptom			~		bed by patient	
symptom	was observed by a he		~	If other facility, specify Sign/symptom was descri Yes		OUnknown
symptom Sign/symptom	was observed by a he	ealth care provider	~	Sign/symptom was descri		O Unknown Delete

Document any neurological or other manifestations of syphilis based on their definitions from above in the fields below:

- Does the patient present with any neurological, ocular (eye), otic (ear), or late clinical manifestations which are consistent with <u>syphilis</u>
- If yes, which:
 - o Neurological manifestations
 - o Ocular manifestations
 - o Otic manifestations
 - o Late clinical manifestations

Neurological / Other Manifestations of Syphilis (Providers)


Does the patient present w	vith any neurological, ocular(eye),	, otic(ear) or late clinical manifest	ations which are consistent with syphilis
O Yes	O No		Unknown
If Yes, which			
Neurological	Ocular(eye)	Otic(ear)	Late clinical manifestations
			mannestations

Cuphilia traatment recommendations

If more than one treatment, add additional t	reatmen	its by using the add button.			
Syphilis Treatment (MANDATORY)					
ID-001					
Was patient treated		Treatment initiation date			
O Yes O No O Unknown					
BIC #2 Date		BIC #3 Date			
CDC First-line Recommended Rx	~				
STI Complication and/or Alternative CDC Recommended R		If other, please specify			
Streemplication and/or Alternative CDC Recommended R	~				
STI condition		Provider Name			
	~				
A manufactor transferrent		Did patient's symptoms resolve			
Appropriate treatment O Yes O No O Unknown		○ Yes ○ No	O Unknown		
		○ N/A			
			Delete		
			Add		

DATA GATHERING FOR DOXY PEP/ HIV PrEP

DoxyPEP a	nd HIV-PrEP					
Is this patient eligi	ible for HIV-PrEP based	on the guidelines?	Is this patient el	ligible for DoxyPEP k	Dased on the guidelines?	
Did the patient red	eive a recommendation	for HIV-PrEP or DoxyPE	P? Ves, PrEP	N/A	Unknown	
If yes, who recominurse, etc.)?	mended (medical provid	er, DIS, investigator,				
Is the patient takin	ng <u>HIV-PrEP</u> ?		Does the patien	t have a prescription	for <u>Doxy-PEP</u> ?	~
Has the patient tal	ken DoxyPEP?	○ N/A	When was the la	ast dose of DoxyPEP)	
Notes						




Questions

Craig Berger Syphilis Surveillance Coordinator / State DIS <u>craig.berger@dhs.wisconsin.gov</u> Phone: 608-266-1323 Fax: 608-261-9301



HAI Prevention Program Contact Information


Email: <u>dhswihaipreventionprogram@dhs.wisconsin.gov</u>





Regional Infection Preventionists

- Western Region: Nikki Mueller, MLS(ASCP)CM, MBA, CIC, Phone: 608-628-4464
- Northern Region: Anna Marciniak, MLS(ASCP), CIC, Phone: 608-590-2980
- Northeastern Region: Tess Hendricks, BS, MLS, CIC, Phone: 608-338-9071
- Southeastern Region: DHSWIHAIPreventionProgram@dhs.wisconsin.gov
- Southern Region: Paula Pintar, MSN, RN, ACNS-BC, CIC, FAPIC, Phone: 608-471-0499







Home > Partners & Providers > Healthcare-Associated Infections: Resources for Health Professionals > HAI Infection Prevention Education

HAI:	Home	

For Health Professionals

For Patients & Families

Infection Prevention Education

Infection Preventionist Starter Kit

Multidrug-Resistant Organisms

Precautions

HAI Data

National Healthcare Safety Network

Antimicrobial Stewardship



Get Handy Hygiene Tips

HAI Infection Prevention Education

The resources below are intended to connect health care facility infection preventionists (IP) with education materials to support their role in preventing, detecting, and responding to healthcare-associated infections (HAI).

IPs play an essential role in facility infection prevention policy development, surveillance, and risk assessment. IPs also serve as a resource to other staff and programs within their facilities.

In addition to the state in-person trainings and online references below, there are a number of links to trusted education resources, including the CDC (Centers for Disease Prevention and Control), the CMS (Centers for Medicare and Medicaid Services), and the Association for Professionals in Infection Control and Epidemiology (APIC).

Monthly webinars for IPs

Long-Term Care Education Series

The Long-Term Care (LTC) Education Series provides education presentations on topics that include infection prevention, HAIs, antibiotic stewardship, disease surveillance, and outbreak response for staff at skilled nursing facilities, assisted living facilities, local health departments, and other LTC stakeholders. Each session features a new, timely topic presented by the Department of Health Services (DHS) program staff, HAI infection preventionists, partner organizations, or other external subject matter experts.

The LTC Education Series is a monthly webinar series, typically held the fourth Thursday of each month. Register for the LTC Education Series 2.

Session recordings

+

IP Lunch and Learn

The IP Lunch and Learn is a webinar series that gives IPs from all care settings the opportunity to come together to discuss introductory infection prevention and control (IPC) topics, as well as share information, network, and ask questions. Each session focuses on a different basic IPC topic area and includes a brief overview with resources and time for attendees to ask questions and share tips and tricks. IPs newer to their role will especially benefit from the information shared.

The IP Lunch and Learn is typically held the second Tuesday of each month. Register for the IP lunch and learn webinar series 🗹.

HAI Infection Prevention Education webpage

Upcoming LTC Education Session

Date: September 26, 2024

Topic: Notes from the Field: Environmental Services in Long-Term Care

